Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

6.3K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
6.3K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

275
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
275
Imaging Studies IV: Magnetic Resonance Imaging01:27

Imaging Studies IV: Magnetic Resonance Imaging

89
Introduction:Magnetic Resonance Imaging, or MRI, can include a specialized imaging technique of the urinary system known as Magnetic Resonance Urography (MRU). This radiation-free technique uses strong magnetic fields and radio waves to produce detailed images with the help of a computer. MRU is particularly effective for visualizing fluid-filled structures like the kidneys, ureters, and bladder.Applications of MRI in the Genitourinary SystemKidneys and Ureters: MRI detects tumors, cysts,...
89
Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

201
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
201
Imaging Studies III: Computed Tomography01:27

Imaging Studies III: Computed Tomography

94
DefinitionComputed Tomography (CT) of the genitourinary (GU) tract is a non-invasive imaging modality that utilizes X-rays and computer processing to generate detailed cross-sectional images of the urinary system, encompassing the kidneys, ureters, bladder, and adjacent structures such as the adrenal glands.PurposeCT scans of the GU tract serve several diagnostic and therapeutic purposes, including:Diagnosis of Urinary Tract Diseases: Detects kidney stones, tumors, cysts, and congenital...
94

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same author

<sup>18</sup>F-Fluciclovine or <sup>68</sup>Ga-PSMA-11 PET/CT-guided Salvage Radiotherapy Changes in Postprostatectomy Biochemical Recurrence: Secondary Analysis of the EMPIRE-2 Trial.

Radiology·2026
Same author

Bladder activity of different PSMA PET radioligands and impact of furosemide.

American journal of nuclear medicine and molecular imaging·2026
Same author

Reply: A Call for High-Level Evidence Before Routine Implementation of Posttreatment SPECT.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Response to the Comment on "Negative 18 F-FES PET/CT Despite Estrogen Receptor Positivity By Immunohistochemistry."

Clinical nuclear medicine·2026
Same author

Inflammatory biomarkers have a prognostic role in patients with metastatic castration-resistant prostate cancer treated with Lutetium-177-PSMA-617.

Cancer·2026

Related Experiment Video

Updated: Oct 24, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.4K

PET Imaging for Prostate Cancer.

Bital Savir-Baruch1, Rudolf A Werner2, Steven P Rowe3

  • 1Division of Nuclear Medicine, Department of Radiology, Loyola University Medical Center, 2160 South 1st Avenue, Maywood, IL 60153, USA.

Radiologic Clinics of North America
|August 16, 2021
PubMed
Summary
This summary is machine-generated.

Positron emission tomography (PET) imaging with advanced radiotracers like prostate-specific membrane antigen (PSMA) significantly enhances prostate cancer detection and influences treatment planning, improving patient outcomes. New PSMA PET agents are increasingly approved for clinical use.

Keywords:
Biochemical recurrenceFluciclovinePET imagingProstate cancerProstate-specific membrane antigenTheranostics

More Related Videos

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

14.6K
A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

512

Related Experiment Videos

Last Updated: Oct 24, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.4K
Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

14.6K
A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

512

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiochemistry

Background:

  • 11C-choline and 18F-fluciclovine PET imaging are established tools for prostate cancer (PCa) evaluation, now included in NCCN guidelines.
  • Prostate-specific membrane antigen (PSMA)-targeted PET tracers are gaining prominence globally for primary PCa and recurrence detection.

Purpose of the Study:

  • To review the evolving role and impact of PET imaging, particularly PSMA-targeted tracers, in prostate cancer management.
  • To highlight the superior diagnostic performance of PET compared to conventional imaging modalities.

Main Methods:

  • Review of current literature and clinical guidelines on PET imaging in prostate cancer.
  • Discussion of approved and emerging PSMA-based PET radiotracers, including 68-Ga-PSMA-11 and 18F-DCFPyL-PET/CT.

Main Results:

  • PET imaging, especially with PSMA tracers, offers higher disease detection rates than CT and MRI.
  • Early data suggest improved patient outcomes with 18F-fluciclovine and PSMA PET imaging.
  • FDA approval of 68-Ga-PSMA-11 and 18F-DCFPyL-PET/CT marks significant advancements in clinical practice.

Conclusions:

  • PSMA-targeted PET imaging is revolutionizing prostate cancer evaluation and treatment planning.
  • The increasing availability and approval of novel PSMA PET agents promise further improvements in patient care for prostate cancer.